Diagnostics News and Research

RSS

SQI Diagnostics closes brokered private placement for gross proceeds of $6,594,786

SQI Diagnostics Inc. (TSX-V: SQD), a medical systems company focused on evolving laboratory-based biomarker testing, today announced that it closed its previously announced, brokered private placement (the "Private Placement") for gross proceeds of $6,594,786.

4 Dec 2009

PLUS Diagnostics expands its specialty anatomic pathology services

PLUS Diagnostics announced today that it has expanded its specialty anatomic pathology services with the launch of a national hematology/oncology offering. The new service completes the company's expansion from a regional laboratory to a leading national anatomic pathology company offering diagnostic services across a full range of specialties including gastroenterology, urology and now hematology/oncology.

4 Dec 2009

Amorfix Life Sciences extends private placement warrants

Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases, announced today it will not accelerate the expiry of the private placement warrants that were issued on April 29, 2009 with a $1.00 exercise price.

4 Dec 2009

New discoveries to treat life-threatening blood disorder presented at ASH annual meeting

A genetic variation that may indicate a patient's risk of developing a potentially life-threatening blood disorder if exposed to certain pharmaceutical therapies or chemicals is one of several medical discoveries scientists at cancer diagnostics leader Quest Diagnostics will present during the 51st American Society of Hematology (ASH) Annual Meeting and Exposition, December 5-8, 2009, in New Orleans, LA.

4 Dec 2009

Advantages of Helicos BioSciences' single molecule sequencing technology presented

Helicos BioSciences Corporation announced today that, as previously disclosed, it has posted a presentation on its website regarding the advantages of Helicos’ single molecule sequencing technology in clinical diagnostics.

4 Dec 2009

Usefulness of heart rate variability as a diagnostic for identifying dysfunction established

According to Dr. Daniel Weiss, a recent study of heart rate autonomic markers, and cardiac mortality published in the November issue of Heart Rhythm provides additional support for the usefulness of heart rate variability as a diagnostic for identifying dysfunction (neuropathy in diabetics and others) and cardiovascular mortality, including fatal arrhythmia or sudden cardiac death.

4 Dec 2009

Biomoda appeals N.M. congressional delegation to support Lung Cancer Mortality legislation

Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD) today urged the New Mexico congressional delegation to support the Lung Cancer Mortality Reduction Act of 2009, which calls for a comprehensive federal program to achieve a 50% reduction in the mortality rate of lung cancer by 2016.

3 Dec 2009

AclarusDx Alzheimer’s test now available as RUO product

ExonHit Therapeutics is pleased to announce that AclarusDx™ Alzheimer’s test (formerly known as EHT Dx21), its blood-based test for the detection of Alzheimer’s disease (AD), is now available as a Research Use Only (RUO) product for pharmaceutical companies and leading academic centers conducting clinical trials in Alzheimer’s disease.

3 Dec 2009

GammaL c device provides accurate lesion localization and facilitates needle-guided biopsy

Breast-Specific Gamma Imaging (BSGI) is a molecular breast imaging technique increasingly being used in the diagnostic workup of patients with indeterminate mammograms and has demonstrated the ability to detect cancers missed by mammography and ultrasound.

2 Dec 2009

Leaders respond to World AIDS Day; South Africa to expand HIV treatment program

Marking World AIDS Day on Tuesday, U.N. Secretary General Ban Ki-Moon "warned ... that new infections are outpacing the gains from treating people with the HIV virus" and that discrimination against HIV-positive people remains "widespread," the Associated Press reports.

2 Dec 2009

Vitro Diagnostics files a patent application for its technology related to generation of iPS cells

Vitro Diagnostics, Inc., dba Vitro Biopharma, announced the filing of a new United States patent application entitled “POU5-F1 Expression in Human Mesenchymal Stem Cells” and the development of new technology related to generation of human induced pluripotent stem cells (iPS).

2 Dec 2009

University of Pittsburgh's McGowan Institute for Regenerative Medicine awarded IBM SUR grant

The University of Pittsburgh's McGowan Institute for Regenerative Medicine, which connects scientists who work on tissue engineering, cell therapies, artificial organs and biodevices, has been awarded a Shared University Research (SUR) Award from IBM ( IBM). The IBM SUR Award will provide IBM computer hardware, software and services to Pitt for its cutting-edge "in silico" biological research, which uses computer simulations to explore biological pathways and test therapeutic interventions.

2 Dec 2009

Coding guidelines for Agendia's MammaPrint test established by Palmetto GBA

Agendia, a world leader in molecular cancer diagnostics, announced today that Palmetto GBA, California's Part B Medicare administrator, has established coding guidelines for the company's MammaPrint test.

2 Dec 2009

A leader in the fight against brain diseases and in drug discovery joins UF

A leader in the fight against brain diseases and in drug discovery to help Alzheimer's patients has joined the University of Florida College of Medicine, interim dean Michael Good, M.D., announced.

2 Dec 2009

FDA approves additional intended use of Roche's cobas TaqScreen MPX Test

Roche announced today that the United States Food & Drug Administration (FDA) approved an additional intended use for its licensed nucleic acid test, to screen source plasma in pools comprised of up to 96 individual donations. The test, called the cobas® TaqScreen MPX Test for use on the cobas s 201 system, is a qualitative, in-vitro test for the simultaneous, direct detection of the human immunodeficiency virus (HIV-1 Group M RNA, HIV-1 Group O RNA , HIV-2 RNA), hepatitis C virus RNA and hepatitis B virus DNA in human plasma.

From Roche Sequencing and Life Science 2 Dec 2009

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Novartis announced today that new data, including a late-breaking presentation on Tasigna® (nilotinib) 200 mg capsules in a form of chronic myeloid leukemia, demonstrate the strength of the company's hematology portfolio in advancing the care of patients.

2 Dec 2009

Occult lesions identified with BSGI can be localized using multi-modality imaging for needle biopsy

Dr. Jocelyn Rapelyea, Associate Director of Breast Imaging and Intervention at George Washington University Medical Center in Washington, D.C., demonstrated how occult lesions identified with Breast-Specific Gamma Imaging (BSGI) can be localized utilizing multi-modality imaging for needle biopsy as well, as for pre-operative localization today at the annual meeting of the Radiological Society of North America (RSNA).

2 Dec 2009

Guardian Technologies International introduces Signature Mapping TBDx to diagnose TB

Guardian Technologies International is bringing the diagnosis of tuberculosis (TB) into the 21st century with Signature Mapping TBDx™ (SM TBDx), an automated diagnostic solution using sophisticated detection algorithms to identify TB under microscopy in sputum samples, at the laboratory level.

2 Dec 2009

BSGI effective in detecting malignant or high-risk lesions in patients with negative mammographic findings

Breast-Specific Gamma Imaging (BSGI) significantly contributes to the detection of malignant or high-risk lesions in patients with negative or indeterminate mammographic findings, according to results of a multicenter study presented today at the annual meeting of the Radiological Society of North America (RSNA).

2 Dec 2009

CRi announces study results of imaging and analysis platform for drug and molecular diagnostic development

Cambridge Research & Instrumentation, Inc. (CRi), a leader in biomedical imaging, today announced the results of a study demonstrating for the first time the capability to detect and automatically measure key activity indicators of cancer cell signal transduction pathways in intact tissue.

2 Dec 2009

Diagnostics News and Research

SQI Diagnostics closes brokered private placement for gross proceeds of $6,594,786

PLUS Diagnostics expands its specialty anatomic pathology services

Amorfix Life Sciences extends private placement warrants

New discoveries to treat life-threatening blood disorder presented at ASH annual meeting

Advantages of Helicos BioSciences' single molecule sequencing technology presented

Usefulness of heart rate variability as a diagnostic for identifying dysfunction established

Biomoda appeals N.M. congressional delegation to support Lung Cancer Mortality legislation

AclarusDx Alzheimer’s test now available as RUO product

GammaL c device provides accurate lesion localization and facilitates needle-guided biopsy

Leaders respond to World AIDS Day; South Africa to expand HIV treatment program

Vitro Diagnostics files a patent application for its technology related to generation of iPS cells

University of Pittsburgh's McGowan Institute for Regenerative Medicine awarded IBM SUR grant

Coding guidelines for Agendia's MammaPrint test established by Palmetto GBA

A leader in the fight against brain diseases and in drug discovery joins UF

FDA approves additional intended use of Roche's cobas TaqScreen MPX Test

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Occult lesions identified with BSGI can be localized using multi-modality imaging for needle biopsy

Guardian Technologies International introduces Signature Mapping TBDx to diagnose TB

BSGI effective in detecting malignant or high-risk lesions in patients with negative mammographic findings

CRi announces study results of imaging and analysis platform for drug and molecular diagnostic development

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News